MERIBEL PHARMA SOLUTIONS
LIVE

Serial Number

98860857

Owner

BW CDMO Holdings UK Limited

Attorney

Amy A. Abeloff

Filing Date

Nov 19, 2024

Add to watchlist:

No watchlists yet
View on USPTO

MERIBEL PHARMA SOLUTIONS Trademark

Serial Number: 98860857

MERIBEL PHARMA SOLUTIONS is a trademark filed by BW CDMO Holdings UK Limited on November 19, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

BW CDMO Holdings UK Limited (2 trademarks)

Suite 1, 7th Floor 50 Broadway
London SW1H0DB , GB

Entity Type: 99

Trademark Details

Filing Date

November 19, 2024

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, diseases of the eyes, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, hereditary disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; biological preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, diseases of the eyes, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, hereditary disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; pharmaceutical substances and preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, diseases of the eyes, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, hereditary diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; vaccines; vaccine preparations; reagents for medical use; diagnostic preparations for medical purposes; diagnostic reagents for medical use; biological preparations for the treatment of cancer; biological preparations for the treatment of viral infections; biological preparations for the treatment of autoimmune diseases; immunotherapeutic drugs, namely, pharmaceutical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, diseases of the eyes, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, hereditary diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; therapeutic and prophylactic pharmaceutical products, for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, diseases of the eyes, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, hereditary diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; pharmaceutical preparations for gene therapy for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, diseases of the eyes, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, hereditary diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, diseases of the eyes, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, hereditary diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders

Scientific and technological services, namely, scientific and technological research and design in the pharmaceutical and biotechnological fields; industrial analysis services, namely, research into the pharmaceutical and biotechnological industries; scientific laboratory services; research and development services in the pharmaceutical and biotechnological fields; pharmaceutical research and development services; research and development in the biotechnology field; biological research, clinical research in the pharmaceutical and biotechnological fields; medical research; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals; scientific research and development in the nature of conducting clinical trials for others; pharmaceutical testing; scientific research and development in the nature of conducting clinical trials for others in the pharmaceutical and biotechnological fields; pharmaceutical drug development services; research and development of pharmaceutical preparations; research and development of vaccines and medicines; research and development of gene-based medicines; research and analysis in the pharmaceutical and biotechnological fields; laboratory research in the pharmaceutical and biotechnological fields; design of manufacturing facilities; pharmaceutical drug development services; quality control for others; laboratory services for genetic engineering; biochemistry laboratories; product development consultancy in the field of pharmaceuticals; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; product development for others; product development for others in the field of viral vectors; product development for others in the field of assays used for scientific analysis; product development consultancy in the field of pharmaceuticals and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, diseases of the eye, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, hereditary diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; product development consultancy in the field of gene therapy, and viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products; provision of information relating to scientific research; provision of scientific information in the pharmaceutical and biotechnological fields; pharmaceutical drug discovery and development services for others; analysis for scientific research in the field of drug discovery and development for others; advisory services in the pharmaceutical and biotechnological fields; scientific research consultancy; pharmaceutical research and development consultancy; consulting services for others in the field of design, planning, and implementation project management of scientific research; consulting services for others in the field of design, planning, and implementation project management of scientific research in the pharmaceutical and biotechnological fields; issuing of scientific information; provision of information and consultancy in relation to the aforesaid services

Custom manufacture of pharmaceuticals; custom manufacture of medicines and vaccines; custom manufacture of products relating to biotechnology in the nature of biological preparations; custom manufacture of pharmaceuticals and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, diseases of the eyes, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, hereditary diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; custom manufacture of pharmaceutical preparations for gene therapy products; custom manufacture of viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products; pharmaceutical contract manufacturing services; biotechnology contract manufacturing services; contract manufacture of pharmaceuticals and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, diseases of the eye, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, hereditary diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; contract manufacture of gene therapy products, and viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 16, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 16, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 16, 2026 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Apr 17, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Apr 17, 2026 XELR
NOTIFICATION OF PRIORITY ACTION E-MAILED
Jan 17, 2026 GPRN
PRIORITY ACTION E-MAILED
Jan 17, 2026 GPRA
PRIORITY ACTION WRITTEN
Jan 17, 2026 CPRA
EXAMINER'S AMENDMENT ENTERED
Nov 11, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 11, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 11, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 11, 2025 CNEA
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Aug 19, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Aug 19, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Aug 19, 2025 CNSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Aug 19, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Aug 19, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Aug 19, 2025 CNSI
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 17, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 17, 2025 CRFA
ASSIGNED TO LIE
Jul 15, 2025 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jul 2, 2025 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 15, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
May 15, 2025 GNSL
SUSPENSION LETTER WRITTEN
May 15, 2025 CNSL
ASSIGNED TO EXAMINER
May 13, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 26, 2025 NWOS
NEW APPLICATION ENTERED
Nov 19, 2024 NWAP